Marshall Wace’s Exagen XGN Stock Holding History

Marshall Wace’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.19M	Buy	392,789 +86,086	+28%	+$553K	﹤0.01%	1575
2026 Q2	$1.43M	Buy	306,703 +279,414	+1,024%	+$1.05M	﹤0.01%	2028
2026 Q1	$81.9K	Sell	27,289 -216,135	-89%	-$836K	﹤0.01%	2926
2025 Q4	$1.48M	Buy	243,424 +218,792	+888%	+$1.99M	﹤0.01%	1734
2025 Q3	$271K	Buy	+24,632	New	+$218K	﹤0.01%	2469
2025 Q2	–	Sell	-106,559	Closed	-$383K	–	3244
2025 Q1	$383K	Buy	106,559 +90,511	+564%	+$342K	﹤0.01%	2178
2024 Q4	$65.8K	Buy	+16,048	New	+$57.8K	﹤0.01%	2473

Other funds holding XGN

Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $140M AUM 44.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

MBAM

Mink Brook Asset Management West Palm Beach, Florida $212M AUM 53.36% 1-Year Est. Return

First Eagle Investment Management New York $63.7B AUM 20.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

F.L. Putnam Investment Management Lynnfield, Massachusetts $9.33B AUM 30.52% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Marshall Wace's XGN Position: Q3 2026 in Review

Marshall Wace increased its Exagen (XGN) stake by 28% in Q3 2026, buying an estimated $553K and bringing the position to 392,789 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #1575.

Marshall Wace first reported a position in XGN in Q4 2024 and has held it in 7 quarters since. 48 funds tracked by Wall St. Rank hold XGN as of Q3 2026.

Marshall Wace held 392,789 shares of Exagen worth $3.19M as of Q3 2026.
Marshall Wace bought 86,086 Exagen shares in Q3 2026, an estimated $553K.
Exagen made up ﹤0.01% of Marshall Wace's portfolio in Q3 2026, its #1575 holding.
Marshall Wace first reported a position in Exagen in Q4 2024 and has held it in 7 quarters since.
48 funds tracked by Wall St. Rank held Exagen as of Q3 2026.

Based on Marshall Wace's 13F filing for Q3 2026, filed 13 Nov 2026.